ADITUM
Enrich your Research

International Journal of Epidemiology and Public Health Research

Research Article

Genomic and Bioinformatic Approaches in the Study of Obesity and Diabetes: Emerging Tools for Precision Medicine

Maria Cidinaria Silva Alves[1]*, Ruana Carolina Cabral da Silva[2]

[1]Laboratório de Bioinformática e Biologia Evolutiva, Centro de Biociências, Departamento de Genética, Universidade Federal de Pernambuco, Recife, 50670-423, Pernambuco, Brazil; orcid.org/0000-0003-0625-416X.

[2]Laboratório de Pesquisa em Ciências da Saúde, Universidade Federal da Grande Dourados, Dourados, 79825-070, Mato Grosso do Sul, Brazil; orcid.org/0000-0003-0435-1871.

Article Information

Received: September 02, 2025
Accepted: September 15, 2025
Published: September 20, 2025

***Corresponding author:** Maria Cidinaria Silva Alves, Laboratório de Bioinformática e Biologia Evolutiva, Centro de Biociências, Departamento de Genética, Universidade Federal de Pernambuco, Recife, 50670-423, Pernambuco, Brazil; orcid.org/0000-0003-0625-416X.

Citation: Silva Alves MC, Cabral da Silva RC., (2025) "Genomic and Bioinformatic Approaches in the Study of Obesity and Diabetes: Emerging Tools for Precision Medicine". International Journal of Epidemiology and Public Health Research, 7(1); DOI: 10.61148/2836-2810/IJEPHR/168.

Abstract

Obesity and type 2 diabetes (T2D) are complex metabolic disorders with multifactorial origins involving genetic, environmental, and behavioral factors. Advances in genomic technologies, especially next-generation sequencing (NGS), have enabled the identification of numerous genetic variants associated with susceptibility to these conditions. At the same time, bioinformatics has become indispensable for managing and interpreting the vast datasets generated by multi-omics studies. Integrative analyses combining genomics, transcriptomics, epigenomics, and proteomics provide deeper insights into disease mechanisms and potential therapeutic targets. Moreover, computational tools such as pathway enrichment analysis, network modeling, and molecular dynamics simulations contribute to identifying novel biomarkers and drug candidates. Despite significant progress, challenges remain in translating these findings into clinical practice, particularly concerning population diversity and data interpretation. This review discusses recent advances in genomic and bioinformatic approaches applied to obesity and diabetes research, emphasizing their contributions to precision medicine.

Key Words: genomics; bioinformatics; obesity; type 2 diabetes; multi-omics integration

Abbreviations: T2D: Type 2 Diabetes; NGS: Next-Generation Sequencing; GWAS: Genome-Wide Association Studies; SNP: Single Nucleotide Polymorphism; FTO: Fat Mass and Obesity-Associated Gene; TCF7L2: Transcription Factor 7-Like 2; WGS: Whole-Genome Sequencing; scRNA-seq: Single-Cell RNA Sequencing; IPA: Ingenuity Pathway Analysis; MOFA: Multi-Omics Factor Analysis; INSR: Insulin Receptor; GLUT4: Glucose Transporter Type 4; PPARγ: Peroxisome Proliferator-Activated Receptor Gamma; VUS: Variant of Uncertain Significance.

Introduction

Obesity and type 2 diabetes (T2D) are major public health concerns worldwide, associated with increased morbidity, mortality, and healthcare costs[1,2]. These metabolic disorders result from complex interactions between genetic predispositions, environmental exposures, and lifestyle factors, making their pathogenesis highly intricate. In this context, genomic and bioinformatic approaches have emerged as essential tools to unravel the molecular underpinnings of these conditions[3–5].

The advent of next-generation sequencing (NGS) technologies has revolutionized our ability to identify thousands of genetic variants linked to obesity and diabetes, including single nucleotide polymorphisms (SNPs) and structural variants[6]. These discoveries have provided valuable insights into metabolic pathways and revealed potential biomarkers for early diagnosis and risk stratification[7]. Longitudinal studies and large population cohorts have further contributed robust data for the identification of genetic signatures associated with complex metabolic phenotypes[8].

Simultaneously, the development of sophisticated bioinformatic pipelines capable of handling large-scale omics datasets has enabled integrative analyses that offer a more holistic understanding of these disorders[9]. This synergy between genomics and bioinformatics is driving a paradigm shift from traditional biomedical models toward precision medicine, where interventions are increasingly personalized and effective[10].

Building upon genomic discoveries, structural bioinformatics is essential for the functional characterization of disease-associated variants by mapping them onto three-dimensional protein structures [11]. This type of approach enables the identification of alterations in key structural domains, binding pockets, or allosteric sites that may affect protein stability, dynamics, or molecular interactions. Tools such as homology modeling, molecular docking, and molecular dynamics simulations allow for the in silico exploration of how specific polymorphisms or post-translational modifications influence protein behavior in the context of obesity and T2D [12,13]. This systems structural biology perspective reinforces the translational impact of bioinformatic approaches, helping to bridge potential gaps between genotype and phenotype [14].

Genomics Applied to Obesity and Diabetes

Genome-wide association studies (GWAS) have significantly advanced our understanding of the genetic basis of obesity and T2D, identifying multiple loci linked to increased disease risk[15,16]. Among the most notable are the FTO (fat mass and obesity-associated) gene, which influences energy balance, and TCF7L2 (transcription factor 7-like 2), a key regulator of insulin secretion and glucose homeostasis[16]. These findings have shed light on fundamental biological mechanisms, such as adipocyte differentiation and insulin sensitivity[17].

However, despite these advances, the identified genetic variants explain only a fraction of the heritability of these diseases, a phenomenon known as the "missing heritability"[18]. This gap suggests the involvement of rare variants with larger effects, as well as gene-gene and gene-environment interactions that remain largely uncharacterized[19]. Functional genomics, integrating data on gene expression, epigenetic regulation, and three-dimensional genome architecture, offers promising avenues to address these limitations.

Additionally, novel technologies such as whole-genome sequencing (WGS) and single-cell RNA sequencing (scRNA-seq) are enabling unprecedented resolution in mapping gene networks and metabolic pathways implicated in obesity and T2D[6,16]. These approaches facilitate the identification of specific cell populations affected by disease processes and reveal intra-tissue molecular heterogeneity, critical for developing more targeted and effective therapies[20] (figure 1).



Figure 1: Overview of genomic approaches in obesity and type 2 diabetes (T2D). GWAS have identified key risk loci, including *FTO* and *TCF7L2*, linked to adipocyte differentiation and insulin sensitivity. The concept of missing heritability highlights the role of rare variants and gene-environment interactions. Functional genomics, together with WGS and scRNA-seq, enables deeper insight into regulatory networks and supports the development of targeted therapies.

Bioinformatics and Integrated Omics

While genomic data alone provide valuable information, they are often insufficient to fully capture the complexity of metabolic disorders[21]. Thus, integrating multiple layers of omics data, including transcriptomics, epigenomics, proteomics, and metagenomics, has become essential in obesity and diabetes research[21,22]. This systems biology approach allows for the characterization of not only genetic predispositions but also dynamic changes induced by environmental and behavioral factors[23].

Numerous bioinformatics tools and pipelines have been developed to support the integration and analysis of these massive

datasets[24]. These resources enable the construction of gene-protein interaction networks, identification of co-expression modules, and prediction of altered metabolic pathways[22]. For instance, combining DNA methylation and transcriptomic profiles has elucidated regulatory mechanisms involved in insulin resistance and adipose tissue accumulation[25,26].

The Table 1 below highlights some key bioinformatic tools used in multi-omics integration for obesity and diabetes research, describing their functions and applications[27–31]:

Table 1: Key Bioinformatic Tools for Multi-Omics Integration in Obesity and Diabetes Research.

Tool	Main Function	Example of Application	References
Ingenuity Pathway Analysis (IPA)	Interaction network analysis, pathway enrichment	Identifying altered metabolic pathways in obese patients with insulin resistance	[27]
Cytoscape	Visualization and analysis of biological networks	Constructing gene-protein networks from adipose tissue transcriptomic data	[28]
Multi-Omics Factor Analysis (MOFA)	Integration of multi-omics data, discovery of latent factors	Integrating methylome and transcriptome to identify epigenetic regulators in T2D	[29]
MetaboAnalyst	Statistical and functional analysis of metabolomic data	Identifying differential metabolites in individuals with severe obesity	[30]
String	Prediction and visualization of protein-protein interactions	Exploring interactions among proteins encoded by obesity-associated genes	[31]

Molecular Modeling and Protein Dynamics

Molecular modeling plays a pivotal role in elucidating the structural features of key proteins involved in the pathophysiology of obesity and T2D[15,16]. Techniques such as homology modeling, molecular docking, and molecular dynamics simulations enable the prediction of three-dimensional protein structures, even when crystallographic data are unavailable[32]. These analyses are instrumental for identifying potential therapeutic targets and for rational drug design[33].

In the context of T2D, structural modeling has been widely applied to investigate interactions between the insulin receptor (INSR) and its ligands, as well as to study regulatory proteins like the glucose transporter GLUT4[34,35]. Similarly, in obesity research, the structural characterization of nuclear receptors involved in adipogenesis, such as PPARγ, has provided critical insights into molecular mechanisms and pharmacological intervention opportunities[36,37].

Molecular dynamics simulations add a temporal dimension to structural studies, allowing the assessment of protein conformational stability and ligand-binding dynamics under physiological conditions[38,39]. These approaches can uncover alterations in structural flexibility due to genetic variants or post-translational modifications, directly impacting protein function[40]. Thus, molecular modeling and dynamics offer a robust framework for exploring new therapeutic avenues in obesity and diabetes[39].

Protein structures and small-molecule ligands can be retrieved from well-established databases such as the RCSB Protein Data Bank (https://www.rcsb.org/) and PubChem (https://pubchem.ncbi.nlm.nih.gov/), respectively. Once collected, these molecular entities can be explored through in silico approaches such as molecular docking and molecular dynamics simulations to investigate their interactions, binding affinities, and conformational behavior in biologically relevant environments (figure 2). These computational strategies are especially valuable for examining protein–ligand and protein–protein interactions, offering mechanistic insights that complement experimental data. In the context of metabolic disorders, such analyses contribute to a deeper understanding of the structural determinants governing molecular recognition and function, ultimately guiding the rational design of targeted therapeutics.



Figure 2: Simplified pipeline for molecular modeling applied to obesity and T2D research. Structures are retrieved from public databases, modeled if necessary, and used in docking and molecular dynamics simulations to explore biomolecular interactions and guide therapeutic development.

Future Perspectives

The integration of genomic, transcriptomic, epigenomic, and proteomic data with clinical information is paving the way for implementing precision medicine in the management of obesity and diabetes[22]. This approach aims to personalize therapeutic strategies based on each individual's molecular and genetic profile, promoting more effective interventions with fewer adverse effects[10]. The development of genetic risk panels and machine learning-based predictive algorithms exemplifies this promising trend[41].

However, translating these technologies into clinical practice still faces significant challenges, such as methodological standardization, functional interpretation of variants of uncertain significance (VUS), and ethical issues related to genetic data privacy[42]. Moreover, population representation in genomic studies remains uneven, with minority ethnic groups often underrepresented, potentially limiting the generalizability of findings and exacerbating health disparities.

Looking ahead, continuous advances in sequencing technologies, coupled with the development of more efficient bioinformatic tools, are expected to enable even more detailed characterization of the molecular mechanisms underlying metabolic diseases. Interdisciplinary collaboration among geneticists, bioinformaticians, clinicians, and public health professionals will be crucial to translate these insights into concrete benefits for the prevention and treatment of obesity and diabetes.

Conclusion

The application of genomic and bioinformatic approaches has significantly advanced our understanding of the molecular mechanisms underlying obesity and diabetes, uncovering new risk loci, altered metabolic pathways, and potential therapeutic targets. The integration of multi-omics data and the use of sophisticated computational tools have expanded the capacity to identify complex interactions between genetic, epigenetic, and environmental factors, contributing to the shift toward precision medicine.

Despite these achievements, several important challenges remain, including the need for greater population diversity in genomic studies, the functional interpretation of rare variants, and the effective clinical translation of bioinformatic discoveries. Strengthening interdisciplinary collaboration, alongside ongoing

technological development, will be essential for transforming genomic knowledge into personalized interventions that enhance the prevention, diagnosis, and treatment of obesity and diabetes, with broad implications for global public health.

Author contributions MCSA: Conceptualization-methodology, performed the literature search, writing original draft. RCCS: Preparation of the figures e writing original draft. . All authors contributed to the review and editing of the manuscript.

Funding No funding received for this work.

Data availability Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Clinical trial number not applicable.

Declarations

Ethical approval No ethical approval was required for this study.

Conflict of interest The authors declare that they have no conflict of interest.

References:

1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol*. 2018;14(2):88-98. doi:10.1038/nrendo.2017.151
2. Sarma S, Sockalingam S, Dash S. Obesity as a multisystem disease: Trends in obesity rates and obesity-related complications. *Diabetes Obes Metab*. 2021;23(S1):3-16. doi:10.1111/dom.14290
3. Rodrigues KF, Yong WTL, Bhuiyan MSA, Siddiquee S, Shah MD, Venmathi Maran BA. Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review. *Biology*. 2022;11(9):1308. doi:10.3390/biology11091308
4. Martins E. Inherited metabolic disorders: a century of evolution. *NASCER E CRESCER - BIRTH GROWTH Med J*. 2020;29(3):126-127. doi:10.25753/BirthGrowthMJ.v29.i3.20653
5. Pillon NJ, Loos RJF, Marshall SM, Zierath JR. Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care. *Cell*. 2021;184(6):1530-1544. doi:10.1016/j.cell.2021.02.012
6. Satam H, Joshi K, Mangrolia U, et al. Next-Generation Sequencing Technology: Current Trends and Advancements. *Biology*. 2023;12(7):997. doi:10.3390/biology12070997
7. Lin C, Tian Q, Guo S, et al. Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification. *Molecules*. 2024;29(10):2198. doi:10.3390/molecules29102198
8. Wahl S, Vogt S, Stückler F, et al. Multi-omic signature of body weight change: results from a population-based cohort study. *BMC Med*. 2015;13(1):48. doi:10.1186/s12916-015-0282-y
9. Ogunjobi TT, Ohaeri PN, Akintola OT, et al. Bioinformatics Applications in Chronic Diseases: A Comprehensive Review of Genomic, Transcriptomics, Proteomic, Metabolomics, and Machine Learning Approaches. *Medinformatics*. Published online February 6, 2024. doi:10.47852/bonviewMEDIN42022335
10. Molla G, Bitew M. Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives. *Biomedicines*. 2024;12(12):2750. doi:10.3390/biomedicines12122750
11. Glusman G, Rose PW, Prlić A, et al. Mapping genetic variations to three-dimensional protein structures to enhance variant interpretation: a proposed framework. *Genome Med*. 2017;9(1):113. doi:10.1186/s13073-017-0509-y
12. Yazar M, Özbek P. In Silico Tools and Approaches for the Prediction of Functional and Structural Effects of Single-Nucleotide Polymorphisms on Proteins: An Expert Review. *Omics J Integr Biol*. 2021;25(1):23-37. doi:10.1089/omi.2020.0141
13. Mustafa HA, Albkrye AMS, AbdAlla BM, Khair MAM, Abdelwahid N, Elnasri HA. Computational determination of human PPARG gene: SNPs and prediction of their effect on protein functions of diabetic patients. *Clin Transl Med*. 2020;9(1):7. doi:10.1186/s40169-020-0258-1
14. Arbitrio M, Milano M, Lucibello M, et al. Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis. *Front Pharmacol*. 2025;16:1548991. doi:10.3389/fphar.2025.1548991
15. Sanghera DK, Blackett PR. Type 2 Diabetes Genetics: Beyond GWAS. *J Diabetes Metab*. 2012;3(198):6948. doi:10.4172/2155-6156.1000198
16. Basile KJ, Johnson ME, Xia Q, Grant SFA. Genetic Susceptibility to Type 2 Diabetes and Obesity: Follow-Up of Findings from Genome-Wide Association Studies. *Int J Endocrinol*. 2014;2014(1):769671. doi:10.1155/2014/769671
17. Tong Q, Hotamisligil GS. Molecular Mechanisms of Adipocyte Differentiation. *Rev Endocr Metab Disord*. 2001;2(4):349-355. doi:10.1023/A:1011863414321
18. Sadee W, Hartmann K, Seweryn M, Pietrzak M, Handelman SK, Rempala GA. Missing heritability of common diseases and treatments outside the protein-coding exome. *Hum Genet*. 2014;133(10):1199-1215. doi:10.1007/s00439-014-1476-7
19. Génin E. Missing heritability of complex diseases: case solved? *Hum Genet*. 2020;139(1):103-113. doi:10.1007/s00439-019-02034-4
20. Hekselman I, Yeger-Lotem E. Mechanisms of tissue and cell-type specificity in heritable traits and diseases. *Nat Rev Genet*. 2020;21(3):137-150. doi:10.1038/s41576-019-0200-9
21. Yang SY, Han SM, Lee JY, Kim KS, Lee JE, Lee DW. Advancing Gut Microbiome Research: The Shift from Metagenomics to Multi-Omics and Future Perspectives. *J Microbiol Biotechnol*. 2025;35:e2412001. doi:10.4014/jmb.2412.12001
22. Mani S, Lalani SR, Pammi M. Genomics and multiomics in the age of precision medicine. *Pediatr Res*. 2025;97(4):1399-1410. doi:10.1038/s41390-025-04021-0
23. Alemu R, Sharew NT, Arsano YY, et al. Multi-omics approaches for understanding gene-environment interactions in noncommunicable diseases: techniques, translation, and equity issues. *Hum Genomics*. 2025;19(1):8. doi:10.1186/s40246-025-00718-9
24. Galán-Vásquez E, Perez-Rueda E. Identification of Modules With Similar Gene Regulation and Metabolic Functions Based

on Co-expression Data. *Front Mol Biosci*. 2019;6. doi:10.3389/fmolb.2019.00139
25. Ling C, Rönn T. Epigenetics in Human Obesity and Type 2 Diabetes. *Cell Metab*. 2019;29(5):1028-1044. doi:10.1016/j.cmet.2019.03.009
26. McAllan L, Baranasic D, Villicaña S, et al. Integrative genomic analyses in adipocytes implicate DNA methylation in human obesity and diabetes. *Nat Commun*. 2023;14(1):2784. doi:10.1038/s41467-023-38439-z
27. Krämer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics*. 2014;30(4):523-530. doi:10.1093/bioinformatics/btt703
28. Shannon P, Markiel A, Ozier O, et al. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. *Genome Res*. 2003;13(11):2498-2504. doi:10.1101/gr.1239303
29. Argelaguet R, Velten B, Arnol D, et al. Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets. *Mol Syst Biol*. 2018;14(6):e8124. doi:10.15252/msb.20178124
30. Xia J, Wishart DS. Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis. *Curr Protoc Bioinforma*. 2016;55(1):14.10.1-14.10.91. doi:10.1002/cpbi.11
31. Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. *Nucleic Acids Res*. 2013;41(D1):D808-D815. doi:10.1093/nar/gks1094
32. Stanzione F, Giangreco I, Cole JC. Chapter Four - Use of molecular docking computational tools in drug discovery. In: Witty DR, Cox B, eds. *Progress in Medicinal Chemistry*. Vol 60. Elsevier; 2021:273-343. doi:10.1016/bs.pmch.2021.01.004
33. Schenone M, Dančík V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. *Nat Chem Biol*. 2013;9(4):232-240. doi:10.1038/nchembio.1199
34. Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. *Signal Transduct Target Ther*. 2022;7:216. doi:10.1038/s41392-022-01073-0
35. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. *Physiol Rev*. 2018;98(4):2133-2223. doi:10.1152/physrev.00063.2017
36. Wen X, Zhang B, Wu B, et al. Signaling pathways in obesity: mechanisms and therapeutic interventions. *Signal Transduct Target Ther*. 2022;7:298. doi:10.1038/s41392-022-01149-x
37. Ahmad B, Serpell CJ, Fong IL, Wong EH. Molecular Mechanisms of Adipogenesis: The Anti-adipogenic Role of AMP-Activated Protein Kinase. *Front Mol Biosci*. 2020;7. doi:10.3389/fmolb.2020.00076
38. Grewal S, Deswal G, Grewal AS, Guarve K. Molecular dynamics simulations: Insights into protein and protein ligand interactions. *Adv Pharmacol San Diego Calif*. 2025;103:139-162. doi:10.1016/bs.apha.2025.01.007
39. Forbes BE. The three-dimensional structure of insulin and its receptor. *Vitam Horm*. 2023;123:151-185. doi:10.1016/bs.vh.2022.12.001
40. Landini A, Trbojević-Akmačić I, Navarro P, et al. Genetic regulation of post-translational modification of two distinct proteins. *Nat Commun*. 2022;13:1586. doi:10.1038/s41467-022-29189-5
41. Kaviyaadharshani D, Nivedhidha M, Jeyarohini R, Rani JLE, Ramkumar MP, Selvan GSRE. Diagnosing Diabetes using Machine Learning-based Predictive Models. *Procedia Comput Sci*. 2024;233:288-294. doi:10.1016/j.procs.2024.03.218
42. Burke W, Parens E, Chung WK, Berger SM, Appelbaum PS. The challenge of genetic variants of uncertain clinical significance: A narrative review. *Ann Intern Med*. 2022;175(7):994-1000. doi:10.7326/M21-4109.